Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
| Status: | Terminated |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/17/2018 |
| Start Date: | August 7, 2007 |
| End Date: | July 28, 2017 |
A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies
The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an
improvement in treatment-related mortality (TRM) rate at 6 months.
improvement in treatment-related mortality (TRM) rate at 6 months.
Inclusion Criteria:
- Patients must have histologically documented AML, ALL, MDS, CML, Acute myeloid
leukemia (AML) with one or more of the following criteria
- CR 1 with poor risk features
- CR 2, or higher order CR
- Acute lymphoblastic leukemia (ALL) with one of the following criteria
- CR 1 with poor risk features
- CR 2, or higher order CR
- Myelodysplasia, RAEB I
- Donor has been identified
- Age ≤ 65 years.
- Performance Status 0-1.
Exclusion Criteria:
- Patients relapsing <6 months after autologous SCT are not eligible.
- Patients with active infections requiring oral or intravenous antibiotics are not
eligible for enrollment until resolution of infection.
- Non-pregnant and non-nursing
We found this trial at
1
site
Click here to add this to my saved trials
